News|Articles|August 10, 2015

Symbiosis Pharmaceutical Services Completes Successful Sterile Inspection

The company’s Scotland-based facility has successfully completed a scheduled inspection by the UK’s MHRA; there were no critical or major observations noted.

Symbiosis Pharmaceutical Services, a CMO in parenteral manufacturing, announced that its Scotland-based facility has successfully completed a scheduled inspection by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). There were no critical or major observations noted.

Symbiosis has been re-inspected and approved for the ongoing production of investigational medicinal products for clinical trials. The company has received confirmation of continued authorization for the GMP manufacture of aseptically-filled licensed commercial products following initial approval of the commercial manufacturer’s/importers license in 2014.

Source: Symbiosis Pharmaceutical Services


Related to this article

CPHI Milan 2026: Trends in Pharma
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.